Fox Run Management L.L.C. Has $778,000 Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

Fox Run Management L.L.C. grew its stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 57.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,739 shares of the company's stock after buying an additional 6,138 shares during the period. Fox Run Management L.L.C.'s holdings in Twist Bioscience were worth $778,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the stock. Van ECK Associates Corp grew its holdings in Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after purchasing an additional 267 shares during the period. Wilmington Savings Fund Society FSB bought a new position in shares of Twist Bioscience during the third quarter worth $34,000. US Bancorp DE grew its holdings in shares of Twist Bioscience by 72.0% in the 4th quarter. US Bancorp DE now owns 1,436 shares of the company's stock valued at $67,000 after buying an additional 601 shares during the period. Beaird Harris Wealth Management LLC bought a new stake in shares of Twist Bioscience in the 3rd quarter valued at $95,000. Finally, KBC Group NV raised its stake in Twist Bioscience by 71.4% during the 4th quarter. KBC Group NV now owns 2,942 shares of the company's stock worth $137,000 after buying an additional 1,226 shares during the period.

Twist Bioscience Stock Down 2.9 %

Shares of NASDAQ:TWST traded down $1.22 during midday trading on Friday, reaching $40.36. The company had a trading volume of 559,838 shares, compared to its average volume of 940,445. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The stock has a market cap of $2.41 billion, a PE ratio of -11.94 and a beta of 2.15. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. The business's 50 day moving average price is $45.15 and its 200 day moving average price is $45.33.

Remove Ads

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. The firm had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business's quarterly revenue was up 24.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.75) EPS. Research analysts forecast that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In related news, CFO Adam Laponis sold 5,886 shares of the firm's stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $43.26, for a total value of $254,628.36. Following the completion of the sale, the chief financial officer now directly owns 110,096 shares in the company, valued at approximately $4,762,752.96. This trade represents a 5.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Robert Chess sold 2,940 shares of Twist Bioscience stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $53.13, for a total value of $156,202.20. Following the transaction, the director now owns 18,173 shares of the company's stock, valued at $965,531.49. The trade was a 13.93 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 33,799 shares of company stock worth $1,593,944 over the last quarter. 3.01% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on TWST shares. JPMorgan Chase & Co. increased their price target on Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a report on Tuesday, February 4th. Barclays set a $58.00 target price on shares of Twist Bioscience and gave the stock an "overweight" rating in a report on Monday, February 3rd. Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Robert W. Baird raised their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a report on Tuesday, February 4th. Finally, Wolfe Research began coverage on Twist Bioscience in a research note on Friday, December 13th. They issued an "outperform" rating and a $60.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $54.40.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.